Leerink Partners analyst Andrew Berens has maintained their bullish stance on ARVN stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Berens has given his Buy rating due to a combination of factors surrounding the promising data from Arvinas Holding Company’s ARV-102. The Phase 1 study results presented at the International Conference on Alzheimer’s and Parkinson’s Diseases highlight the drug’s pharmacokinetic and pharmacodynamic profiles, as well as its safety in healthy volunteers. ARV-102 demonstrated effective absorption and significant reductions in LRRK2 levels, a key target in neurodegenerative diseases, which supports its potential efficacy.
Moreover, the safety profile of ARV-102 appears favorable, with no serious adverse events reported, and the treatment-related adverse events being manageable. The comparison with BIIB122, another LRRK2 inhibitor, shows that ARV-102’s safety data is comparable, if not better, given the lower incidence of adverse events. These positive indicators, combined with the drug’s potential to penetrate the blood-brain barrier and engage the LRRK2 pathway effectively, underpin Berens’s optimistic outlook and Buy rating for Arvinas Holding Company.
In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $28.00 price target.
ARVN’s price has also changed dramatically for the past six months – from $24.960 to $6.560, which is a -73.72% drop .